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bDepartment of Biostatistics, Hyogo College of Medicine, Nishinomiya, JapanReceived 22 March 2015; accepted 25 May 2015; online published-ahead-of-print 7 July 2015Background It is well-documented that persistent myocardial hypertrophy in patients with aortic stenosis is related to
suboptimal postoperative outcomes after aortic valve replacement. Although diabetes is known to poten-
tially exacerbate myocardial hypertrophy, it has yet to be examined if it affects postoperative left ventricular
mass regression (LVMR).
Methods A single-centre, retrospective analysis was performed on 183 consecutive patients who underwent either
surgical or transcatheter aortic valve replacement between 2010 and May 2013. Patient demographics,
postoperative outcomes and echocardiographic data were obtained preoperatively and a year after surgery.
Results There were 42 diabetic and 141 non-diabetic patients. Preoperative characteristics of diabetic patients were
statistically similar to those of non-diabetic patients, except for higher prevalence of hyperlipidaemia
(p <0.001) and history of cerebrovascular disorder (p=0.046) in diabetic patients. Median value of post-
operative LVMR of all patients was -36.5 g/m2, and was significantly greater in the non-diabetics compared
to the diabetics (-39.1 vs. -22.2 g/m2, p=0.008). Univariate and multivariate analyses were performed on
preoperative variables, and stepwise multiple regression analysis demonstrated that diabetes (standardised
partial regression coefficient (SPRC)=-0.187, p=0.018), female gender (SPRC=0.245, p=0.026) and age
(SPRC=0.203, p=0.018) were associated with poor postoperative LVMR.
Conclusions Patients with diabetes showed suboptimal postoperative LVMR, and the disease was a prognostic factor
that was associated with poor LVMR. These findings suggest that diabetes may predispose the particular
group of patients to worse postoperative outcomes.
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In patients with aortic stenosis, the most crucial pathological
determinant is a chronic pressure overload onto the left
ventricle caused by the calcified, immobile aortic valve, lead-
ing to concentric hypertrophy and myocardial fibrosis [1].
Aortic valve replacement (AVR), either surgical or using a
transcatheter approach, is the sole definitive treatment for
aortic stenosis that results in immediate relief of mechanical
obstruction [1]. Aortic valve replacement usually elicits a
postoperative reverse remodelling of the hypertrophic myo-
cardium, i.e., left ventricular mass regression (LVMR) [2,3]. It
occurs early after surgery and continues up to 10 years [2].
However, persistent residual left ventricular hypertrophy is
not uncommon despite successful AVR [4,5]. Suboptimal
LVMR is known to be associated with late cardiac events
and poor long-term outcomes [4,5]. From the physiological
point-of-view, the majority of studies have focussed on
patient-prosthesis mismatch, which is defined as the effective
orifice area of a normally functioning prosthesis being too
small for a patient’s body size. Patients who are complicated
with patient-prosthesis mismatch have reduced LVMR after
AVR and worse exercise capacity compared with patients
without mismatch [6,7]. Although afterload relief and sub-
sequent LVMR are mostly attributed to prosthetic valve
function, it has been relatively undetermined if various pre-
operative and/or perioperative patient factors affect poor
post-AVR LVMR.
Diabetes is the most prevalent metabolic disorder that
affects more than 300 million patients worldwide, and is
well-known to increase the risk of various cardiovascular
disorders and heart failure. It has been shown that diabetes
exacerbates arterial stiffening and atherosclerotic disease
[8,9], and also plays a role in accelerating myocardial remod-
elling and hypertrophy [10]. In addition, diabetes is a risk
factor of progression of calcification and stenosis of the aortic
valve [11,12]. Considering these findings, one could specu-
late that diabetes may alter the pathophysiological process of
aortic stenosis, thereby worsening postoperative outcomes.
In the present study, we investigate if diabetes is associated
with postoperative myocardial remodelling and LVMR after
surgical AVR (SAVR) or transcatheter AVR (TAVR) for aortic
stenosis, mainly focussing on postoperative echocardio-
graphic findings.
Materials and Methods
One-hundred-and-eighty-three consecutive patients who
underwent SAVR or TAVR for aortic stenosis at Osaka
University hospital between January 2010 and May 2013
were retrospectively analysed. Patients who underwent
simultaneous operations for other valves, thoracic aorta
and maze procedures were excluded from this study. All
the data were retrospectively obtained from the medical
records. The Institutional Review Board approved this study
and patient consent was waived due to its retrospective
nature. Definition of each preoperative comorbidity was asfollows: hypertension, blood pressure >140/90 mmHg or
current use of antihypertensive medication; hyperlipidae-
mia, total cholesterol level >220 mg/dl or triglyceride level
>150 mg/dl or current use of lipid-lowering medication;
diabetes mellitus, fasting plasma glucose level >126 mg/
dl, plasma glucose level (at any time) >200 mg/dl, or current
use of anti-diabetic medication including insulin; left ven-
tricular dysfunction, left ventricular ejection fraction < 50%.
Creatinine clearance was calculated by the Cockcroft-Gault
formula [13].
Surgical AVR was performed using standard cardiopulmo-
nary bypass with bicaval and aortic cannulation under tepid
temperature. Antegrade and retrograde blood cardioplegia
was administered every 20 to 30 minutes to maintain cardiac
arrest. All prosthetic valves were implanted in a supra-annular
position, using multiple non-everting, interrupted 2-0 braided
sutures with pledgets. Types of prosthetic valves were selected
based on surgeon’s preference. In most cases, a bioprosthetic
valve was used unless patients desired otherwise. Transcath-
eter AVR was performed using either the Medtronic Core-
Valve or the Edwards Sapien XT prosthesis, which has been
described in detail elsewhere [14]. Vascular access options for
device placement were the trans-femoral, trans-subclavian
and trans-aortic route. Cardiopulmonary bypass was used
for patients with severe left ventricular dysfunction.
Standard two-dimensional transthoracic echocardiogra-
phy was performed preoperatively and postoperatively,
according to guidelines of the American Society of Echocar-
diography [15]. As postoperative LVMR occurs within one
year after AVR and left ventricular mass tends to become
stable thereafter [4], echocardiographic data was collected
preoperatively and 12 months after surgery. Pressure gradi-
ent across the aortic valve was calculated using a simplified
Bernoulli equation. Left ventricular internal diameter, left
ventricular posterior wall thickness, interventricular wall
thickness and left ventricular ejection fraction were mea-
sured by standard M-mode study. Left ventricular mass
was calculated by a formula reported by Devereux and
colleague [16]. Then each calculated value was indexed to
body surface area (g/m2). Left ventricular mass regression
was accessed by subtracting preoperative from postoperative
indexed left ventricular mass (LVMI).
Statistical analyses were performed using JMP1 10 (SAS
Institute Inc., Cary, NC). Since all the continuous variables
did not fit a standard normal distribution, these are sum-
marised as medians with minimums and maximums. The
continuous variables were compared using the Mann-
Whitney U test. Categorical variables are expressed as fre-
quencies with proportions, and were compared using a chi-
square test. In order to examine preoperative potential risk
factors of poor postoperative LVMR, univariate analyses
were performed using a Mann-Whitney U test and a linear
correlation analysis for the categorical and the continuous
factors, respectively. Preoperative and postoperative echocar-
diographic data were compared using Wilcoxon signed-rank
test. A multiple linear regression model was used to select
preoperative risk factors of LVMR. Factors with p values less
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in the model, and forward selection and backward elimination
methods were used to choose the explanatory variables.
Statistical data were reviewed by a statistician who has con-
siderable expertise in medical research (T.D.). On each statis-
tical analysis, test of significance was two-sided, and a p value
of < 0.05 was considered statistically significant.Results
Patient characteristics are shown in Table 1. Median age was
79 years old and 43.7% of patients were male. Forty-two
patients (30.0%) were diabetic and 141 (70.0%) were non-
diabetic. There was no difference in age, gender, and body
mass index between the two groups. There were significantly
more patients with hyperlipidaemia and history of cerebro-
vascular disorders in diabetic group than non-diabetics.
There was a higher prevalence of hypertension in patients
with diabetes compared with those without, although the
differences did not reach statistical significance. There was
no significant difference in New York Heart Association
functional class, left ventricular dysfunction, chronic obstruc-
tive pulmonary disease, pulmonary hypertension and coro-
nary disease between the groups. Despite a higher
prevalence of the comorbidities in diabetic patients, there
was no significant difference in EUROScore II between the
groups. Comparison of postoperative parameters and earlyTable 1 Patient demographics and echocardiographic data.
Variables a All (n=183) No
Age, years 79 (16-94) 79
Male 80 (43.7) 63
BMI, kg/m2 22.5 (13.0-38.2) 22
Hypertension (%) 140 (76.5) 103
Hyperlipidaemia (%) 72 (39.3) 44
CCr, mg/ml 41.1 (3.2-140.8) 41
Haemodialysis (%) 21 (11.5) 14 
NYHA class 
I 26 (14.2) 21
II 96 (52.5) 74
III 57 (31.2) 42
IV 4 (2.2) 4
COPD (%) 43 (23.5) 34
LV dysfunction (%) 29 (15.9) 22
Cerebrovascular disorder (%) 19 (10.4) 11
Pulmonary hypertension (%) 52 (28.4) 42
EUROScore II 3.25 (0.62-40.9) 3
Coronary disease (%) 83 (45.4) 601
BNP, pg/ml 225 (9.1-5308.2) 228
aCategorical values are expressed as number (%), and continuous values as median
BMI, body mass index; CCr, creatinine clearance; NYHA, New York Heart Associa
brain natriuretic polypeptide.operative results are shown in Table 2. The ratio of con-
comitant coronary artery bypass grafting was significantly
higher in the diabetic group compared with the non-diabetic
group. Early postoperative outcomes including transfusion,
ICU stay, and various complications such as prolonged ven-
tilation, reoperation for bleeding, atrial fibrillation, stroke,
and renal failure were not significantly different between the
two groups. Operative death was 2 (1.1%) in this series, and
there was no significant difference between the groups.
Echocardiography was performed preoperatively and a
year after the operation. Compared with preoperative values,
left ventricular dimension (47 vs. 45 mm, p<0.001), wall thick-
ness of interventricular septum (12 vs. 10 mm, p<0.001), pos-
terior ventricular wall thickness (11 vs. 10 mm, p<0.001), left
ventricular mass index (162.1 vs. 128.0 g/m2, p<0.001), E/e’
(15.1 vs. 14.1, p=0.002), ejection fraction (65 vs. 67%, p=0.002),
aortic valvular area (0.7 vs. 1.6 cm2, p<0.001) and peak aortic
gradient (89 vs. 23 mmHg, p<0.001) significantly improved a
year after operation. Postoperative changes in these echocar-
diographic parameters were compared between the patient
groups with or without diabetes (Table 3). The changes (the
absolute values) in the posterior wall thickness and left ven-
tricular mass index (i.e., LVMR) were significantly greater in
non-diabetic patients than in diabetics (Table 3). Interestingly,
other relevant haemodynamic parameters such as left ventric-
ular ejection fraction, aortic valvular area or peak aortic gradi-
ent were not significantly different between the groups,
suggesting that the difference in LVMR between the two diabetes (n=141) Diabetes (n=42) p value
.0 (16-94) 78.5 (58-89) 0.459
 (44.7) 17 (40.5) 0.724
.4 (13.0-38.2) 22.6 (16.0-29.0) 0.308
 (73.1) 37 (88.1) 0.061
 (31.2) 28 (66.7) < 0.001
.3 (3.2-140.8) 35.1 (3.2-124.0) 0.327
(9.9) 7 (16.7) 0.268
0.624
 (14.9) 5 (11.9)
 (52.5) 22 (52.4)
 (29.8) 15 (35.7)
 (2.8) 0
 (24.1) 9 (21.4) 0.837
 (15.6) 7 (16.8) 0.815
 (7.8) 8 (19.1) 0.046
 (29.8) 10 (23.8) 0.560
.16 (0.62-28.7) 3.52 (0.78-40.9) 0.378
 (42.5) 23 (54.8) 0.216
.2 (9.1-5308.2) 207.1 (24.0-1804.0) 0.344
 (minimum and maximum).
tion; LV, left ventricle; COPD, chronic pulmonary obstructive disease; BNP,
Table 2 Operative and postoperative parameters.
Variablesa All (n=183) No diabetes (n=141) Diabetes (n=42) p value
Type of operation 0.214
SAVR (%) 105 (57.4) 77 (54.6) 28 (66.7)
TAVR (%) 78 (42.6) 64 (45.4) 14 (33.3)
Prosthetic size, mm 23 (19-29) 23 (19-29) 21 (19-29) 0.546
Reoperation (%) 15 (8.2) 11 (7.8) 4 (9.5) 0.751
Urgent operation 5 (2.7) 2 (1.4) 3 (7.4) 0.080
Concomitant CABG (%) 36 (19.7) 23 (16.3) 13 (31.0) 0.047
Operation time, minutes 206 (51-547) 199 (51-530) 238.5 (67-547) 0.099
CPB time, minutes 147 (0-311) 146 (0-311) 148 (0-289) 0.272
AC time, minutes 102 (0-220) 101 (0-394) 104 (0-220) 0.067
Transfusion (%) 155 (84.7) 121 (85.8) 34 (81.0) 0.467
ICU stay, days 2 (0-85) 1 (0-85) 2.5 (0-21) 0.095
Complications
Prolonged ventilation (%) 32 (17.5) 23 (16.3) 9 (21.4) 0.489
Reoperation for bleeding 7 (3.8) 7 (5.0) 0 0.354
Atrial fibrillation (%) 46 (25.1) 38 (27.0) 8 (19.1) 0.300
Stroke (%) 2 (1.1) 2 (1.4) 0 > 0.999
Renal failure (%) 6 (3.3) 4 (2.8) 2 (4.8) 0.622
Operative death (%) 2 (1.1) 2 (1.4) 0 > 0.999
aCategorical values are expressed as number (%), and continuous values as median (minimum and maximum).
AVR, aortic valve replacement; TAVR, trans-catheter aortic valve replacement; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; AC, aortic
clamp; ICU, intensive care unit.
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(Table 3).
In order to examine the potential impact of diabetes on
LVMR, univariate and multivariate analyses were per-
formed using preoperative or perioperative parameters.
Univariate analysis of categorical variables showed that
female gender and diabetes were significantly associated
with poor LVMR (Table 4). Postoperative medications such
as angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker were not related to LVMR. Likewise,Table 3 Change in echocardiographic parameters between pr
Parameters All N
DLVDd, mm -1 (-19, 8) 
DIVSWT, mm -1 (-9, 3) 
DPWT, mm -2 (-8, 4) 
DLVMI, g/m2 -36.5 (-183.2, 62.9) -3
DE/e’ -0.8 (-18.9, 23.6) 
DLVEF, % 2.0 (-32, 40) 
DAVA, cm2 0.9 (-0.1, 3.0) 
DPeak aortic gradient, mmHg -65.6 (-164.3, 8.9) -6
The numbers are expressed as median (minimal and maximal).
LVDd, left ventricular dimension in diastole; IVSWT, wall thickness of interventricu
LVEF, left ventricular ejection fraction; AVA, aortic valve area.correlations between each continuous variable and LVMR
were analysed (Table 5). Age was positively correlated
with LVMR, whereas other preoperative variables did
not correlate with LVMR. To further examine if these
parameters are associated with LVMR, stepwise multiple
linear regression analysis was performed. Among the pre-
operative factors that achieved p values less than 0.2 on
univariate analyses, female gender, the older age and dia-
betes were independently associated with poor LVMR
(Table 6).eoperative and postoperative examinations.
o diabetes Diabetes p value
-1 (-19, 8) -2 (-11, 8) 0.970
-1 (-9, 3) -1 (-4, 2) 0.117
-2 (-8, 2) -1 (-5, 4) 0.045
9.1 (-183.2, 62.9) -22.2 (-120.5, 26.4) 0.008
-0.9 (-18.9, 10.1) -0.25 (-15.4, 23.6) 0.976
2.5 (-32, 40) 0 (-18, 16) 0.208
0.9 (-0.1, 3.0) 1.0 (0, 1.8) 0.774
7.3 (-164.3, 8.9) -51.6 (-136.4, -12.8) 0.069
lar septum; PWT, posterior wall thickness; LVMI, left ventricular mass index;
Table 4 Univariate analysis of preoperative and peri-
operative categorical variables for LVMR.
Variables a LVMR (Dg/m2) p value
Gender 0.003
Male -47.2
Female -25.8
Hypertension 0.184
Yes -34.4
No -42.6
Hyperlipidaemia 0.882
Yes -36.8
No -35.9
Diabetes 0.008
Yes -22.2
No -39.1
LV dysfunction 0.560
Yes -47.0
No -35.0
COPD 0.211
Yes -46.2
No -33.7
Congestive heart failure 0.211
Yes -47.8
No -34.4
Pulmonary hypertension 0.327
Yes -34.6
No -41.8
Coronary disease 0.516
Yes -38.2
No -32.8
Medication
ACEI/ARB 0.538
Yes -33.6
No -38.3
Beta blocker 0.653
Yes -38.3
No -33.7
Statin 0.662
Yes -41.2
No -32.9
* Data are expressed as median of left ventricular mass regression at 1 year.
LVMR. Left ventricular mass regression; LV, left ventricle; COPD, chronic
pulmonary obstructive disease; ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker.
Table 6 Multiple linear regression analysis for LVMR.
SPRC SE 95% CI p value
Female gender 0.245 3.383 3.680 to 17.051 0.026
Age 0.203 0.308 0.127 to 1.344 0.018
Diabetes (no) -0.187 3.980 -17.400 to -1.670 0.018
Hypertension 0.022 4.240 -7.245 to 9.517 0.789
EUROScore II -0.002 0.614 -1.396 to 1.032 0.768
LVMR, left ventricular mass regression; SPRC, standardised partial regres-
sion coefficient; SE, standard error; CI, confidence interval.
Table 5 Univariate analysis of continuous variables for
LVMR.
correlation coefficient p value
Age 0.169 0.021
BMI -0.015 0.853
CCr -0.047 0.567
EUROScore II 0.105 0.196
BNP* -0.098 0.231
*Log transformation was carried out for linear correlation analysis due to
the highly skewed distribution of BNP.
LVMR, left ventricular mass regression; BMI, body mass index; CCr, crea-
tinine clearance; BNP, brain natriuretic polypeptide.
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In the present study, we observed that significant LVMR
occurred and left ventricular mass index normalised in a
half of the patients one year after SAVR or TAVR. The
median value of LVMR was -32 g/m2, which is comparable
with what were described in previous reports [3–7]. How-
ever, as many as 50% of the patients sustained excessive
hypertrophy even after successful surgery. Although thepathophysiologic basis is largely undetermined, previous
reports described that a substantial number of patients exhib-
ited suboptimal postoperative LVMR [4–6]. In the present
study, we explored if preoperative patient demographics
may help in predicting inadequate recovery of hypertrophic
myocardium, and found that diabetes was one of the inde-
pendent predictors of poor postoperative LVMR. The effect
of diabetes was not related to other physiological parameters
such as aortic valvular area or aortic gradient that could
pertain to LVMR. To our knowledge, this is the first report
demonstrating a close link between diabetes and decreased
postoperative LVMR.
Numerous studies have focussed on the size and effective
orifice area of prostheses, namely, patient-prosthesis mis-
match, to analyse incomplete LVMR after AVR [6,7]. There
are compelling evidences that a smaller effective orifice area
causes insufficient reverse remodelling and LVMR [6,7].
On the other hand, the degree of LVMR also seems, at
least in part, to be predetermined by the presence of irrevers-
ible myocardial hypertrophy. For example, various non-
haemodynamic factors such as metabolic disorders are attrib-
uted to pathophysiology of myocardial hypertrophy [17].
Notably, a number of studies revealed that diabetes
adversely affected myocardial hypertrophy and function
in different pathological conditions including AS [8–10,18].
Although the presented data did not suffice to prove the
plausible mechanisms underlying impaired postoperative
regression of myocardial hypertrophy in diabetic patients,
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diabetes and myocardial hypertrophy. For example, there are
evidences that diabetes plays a role in the process of myo-
cardial fibrosis in hypertrophic remodelling by accumulating
extracellular matrix within the hypertrophied myocardium
[19,20]. Falca˜o-Pires and colleagues showed that collagen
volume fraction and intramyocardial vascular advanced gly-
cation end-point product deposition are increased in diabetic
patients with aortic stenosis [20]. Moreover, there are a num-
ber of studies demonstrating that chronic hyperglycaemia
causes oxidative stress on cardiomyocytes, leading to mito-
chondrial damage and cell death [20]. These findings may
propose the potential mechanisms of irreversible myocardial
fibrosis and hypertrophy in diabetic patients, and one could
hypothesise that diabetes may reduce the ability of the myo-
cardium to adapt to the haemodynamic unloading by AVR.
Therefore, it is intriguing if earlier surgical intervention in
diabetic patients could prevent further progression of myo-
cardial fibrosis and hypertrophy, and consequently improve
LVMR.
Another notable finding was that age and gender were
associated with postoperative LVMR. Surprisingly, only a
few studies have demonstrated that older age is a potential
risk factor of incomplete LVMR previously [21]. Further
studies are warranted if older AS patients have decreased
LVMR, and if the possible underlying mechanisms exist in
older patients such as more advanced fibrosis. It was also
shown that female gender was associated with poor LVMR,
which is controversial based on previous reports [22,23].
Female gender is usually less prone to myocardial hypertro-
phy in various cardiac diseases, and this is mainly due to the
protective effects of oestrogen on cardiomyocytes and fibro-
blasts [24]. Such advantages of oestrogen appear to be dimin-
ished after menopause [25]. Actually, female gender exhibits
an increased risk of myocardial hypertrophy caused by
hypertensive stress after menopause [26]. Considering that
the median age of our patients is 75 years old and is relatively
older than previous studies, it is possible that the gender
difference that may exist in a peri-menopause period is no
longer the case in this particular study. Moreover, female
patients had a smaller valvular size and postoperative gra-
dient was higher, which partially explains why female gen-
der was a risk factor of poor postoperative LVMR. This could
have been improved by more judicious use of an annular
extension technique and implantation of a larger size of
prosthesis. Further studies may clarify if age and gender
are to be risk factors of irreversible hypertrophy in AS
patients.
This study had a number of limitations. The major draw-
backs of the study include a single centre, retrospective
analysis, and the small number of patients in a short period
of time. We included both SAVR and TAVR cases in this
study, which may not provide the same haemodynamic
performance. There are no long-term follow-up data to dem-
onstrate if diabetes and inadequate LVMR affected survival
or any adverse cardiac event. Propensity score matching was
not possible due to the small number of patients in eachgroup. Histological specimens were not available, which
might have demonstrated the potential mechanisms of
decreased LVMR by diabetes. Two-dimensional echocardio-
graphic data was the only modality to examine myocardial
hypertrophy and remodelling. Postoperative trans-valvular
aortic gradient or aortic valvular area did not correlate with
LVMR, and these postoperative haemodynamic parameters
were not included in the multivariate analysis. However, we
do not exclude the possibility that these haemodynamic
parameters may have acted as the confounders and affected
the results. Finally, the stages of diabetes and its treatment
were diverse and were not considered in the analysis.Conclusion
Diabetes is one of the independent predictors of suboptimal
LVMR a year after AVR. Further studies are warranted to
address the potential mechanisms behind negative effects of
diabetes on myocardial reverse remodelling. It is also of
interest to examine whether an earlier surgical intervention
or stringent glycaemic control on diabetic patients may
improve LVMR as well as the long-term outcome of AVR.Acknowledgment
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